These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37586448)

  • 21. Inhibition of Src impairs the growth of met-addicted gastric tumors.
    Bertotti A; Bracco C; Girolami F; Torti D; Gastaldi S; Galimi F; Medico E; Elvin P; Comoglio PM; Trusolino L
    Clin Cancer Res; 2010 Aug; 16(15):3933-43. PubMed ID: 20628031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycomic analysis of gastric carcinoma cells discloses glycans as modulators of RON receptor tyrosine kinase activation in cancer.
    Mereiter S; Magalhães A; Adamczyk B; Jin C; Almeida A; Drici L; Ibáñez-Vea M; Gomes C; Ferreira JA; Afonso LP; Santos LL; Larsen MR; Kolarich D; Karlsson NG; Reis CA
    Biochim Biophys Acta; 2016 Aug; 1860(8):1795-808. PubMed ID: 26721331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancing the chemotherapy effect of Apatinib on gastric cancer by co-treating with salidroside to reprogram the tumor hypoxia micro-environment and induce cell apoptosis.
    Zhang Z; Yang W; Ma F; Ma Q; Zhang B; Zhang Y; Liu Y; Liu H; Hua Y
    Drug Deliv; 2020 Dec; 27(1):691-702. PubMed ID: 32397840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
    J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Recepteur D'origine Nantais on Gastric Cancer Development and Progression.
    Yang SY; Nguyen TT; Ung TT; Jung YD
    Chonnam Med J; 2017 Sep; 53(3):178-186. PubMed ID: 29026705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells.
    Xu S; Cui F; Huang D; Zhang D; Zhu A; Sun X; Cao Y; Ding S; Wang Y; Gao E; Zhang F
    Int J Nanomedicine; 2019; 14():17-32. PubMed ID: 30587982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strengthening Gastric Cancer Therapy by Trastuzumab-Conjugated Nanoparticles with Simultaneous Encapsulation of Anti-MiR-21 and 5-Fluorouridine.
    Hu N; Yin JF; Ji Z; Hong Y; Wu P; Bian B; Song Z; Li R; Liu Q; Wu F
    Cell Physiol Biochem; 2017; 44(6):2158-2173. PubMed ID: 29241186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
    Ji F; Liu X; Wu Y; Fang X; Huang G
    Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon.
    Wu P; Zhou Q; Zhu H; Zhuang Y; Bao J
    BMC Cancer; 2020 Apr; 20(1):354. PubMed ID: 32345258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
    Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
    Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.
    Corso S; Ghiso E; Cepero V; Sierra JR; Migliore C; Bertotti A; Trusolino L; Comoglio PM; Giordano S
    Mol Cancer; 2010 May; 9():121. PubMed ID: 20500904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A systematic approach to therapeutic target selection in oesophago-gastric cancer.
    Paterson AL; Shannon NB; Lao-Sirieix P; Ong CA; Peters CJ; O'Donovan M; Fitzgerald RC
    Gut; 2013 Oct; 62(10):1415-24. PubMed ID: 22773546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
    Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
    J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.
    Zarei O; Benvenuti S; Ustun-Alkan F; Hamzeh-Mivehroud M; Dastmalchi S
    J Cancer Res Clin Oncol; 2016 Dec; 142(12):2429-2446. PubMed ID: 27503093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of METase-pemetrexed-loaded PEG-PLGA nanoparticles modified with anti-CD133-scFV for treatment of gastric carcinoma.
    Xin L; Zhang HT; Yang WF; Li YF; Liu C
    Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29229675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease.
    Shrestha N; Xu Y; Prévost JRC; McCartney F; Brayden D; Frédérick R; Beloqui A; Préat V
    Acta Biomater; 2022 Mar; 140():561-572. PubMed ID: 34923097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upregulation of recepteur d'origine nantais tyrosine kinase and cell invasiveness via early growth response-1 in gastric cancer cells.
    Lee KE; Park JS; Khoi PN; Joo YE; Lee YH; Jung YD
    J Cell Biochem; 2012 Apr; 113(4):1217-23. PubMed ID: 22095683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Codelivery of salinomycin and docetaxel using poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles to target both gastric cancer cells and cancer stem cells.
    Li L; Cui D; Ye L; Li Y; Zhu L; Yang L; Bai B; Nie Z; Gao J; Cao Y
    Anticancer Drugs; 2017 Oct; 28(9):989-1001. PubMed ID: 28692437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. O-glycans truncation modulates gastric cancer cell signaling and transcription leading to a more aggressive phenotype.
    Freitas D; Campos D; Gomes J; Pinto F; Macedo JA; Matos R; Mereiter S; Pinto MT; Polónia A; Gartner F; Magalhães A; Reis CA
    EBioMedicine; 2019 Feb; 40():349-362. PubMed ID: 30662000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.